High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: High-dose therapy with supporting autologous stem-cell transplantation remains a controversial treatment for cancer. In multiple myeloma, first-line regimens incorporating high-dose therapy yield higher remission rates than do conventional-dose treatments, but evidence that this translates into improved survival is limited. METHODS: In this multicenter study, the Medical Research Council Myeloma VII Trial, we randomly assigned 407 patients with previously untreated multiple myeloma who were younger than 65 years of age to receive either standard conventional-dose combination chemotherapy or high-dose therapy and an autologous stem-cell transplant. RESULTS: Among the 401 patients who could be evaluated, the rates of complete response were higher in the intensive-therapy group than in the standard-therapy group (44 percent vs. 8 percent, P<0.001). The rates of partial response were similar (42 percent and 40 percent, respectively; P=0.72), and the rates of minimal response were lower in the intensive-therapy group than in the standard-therapy group (3 percent vs. 18 percent, P<0.001). Intention-to-treat analysis showed a higher rate of overall survival (P=0.04 by the log-rank test) and progression-free survival (P<0.001) in the intensive-therapy group than in the standard-therapy group. As compared with standard therapy, intensive treatment increased median survival by almost 1 year (54.1 months [95 percent confidence interval, 44.9 to 65.2] vs. 42.3 months [95 percent confidence interval, 33.1 to 51.6]). There was a trend toward a greater survival benefit in the group of patients with a poor prognosis, as defined by a high beta2-microglobulin level (more than 8 mg per liter). CONCLUSIONS: High-dose therapy with autologous stem-cell rescue is an effective first-line treatment for patients with multiple myeloma who are younger than 65 years of age.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ASCT improves median OS in multiple myeloma by approximately 12 months.125–128”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [126]
Citations
Cites
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Fermand, J.-P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., et al. (1998) · Blood · doi:10.1182/blood.v92.9.3131 · Cited by 542
Barlogie, B., Jagannath, S., Vesole, D. H., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J., et al. (1997) · Blood · doi:10.1182/blood.v89.3.789 · Cited by 541
HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA
MCELWAIN, T. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90739-0 · Cited by 510
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55.401k04_55_65 · Cited by 502
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55 · Cited by 472
Facon, T., Avet-Loiseau, H., Guillerm, G., Moreau, P., Geneviève, F., Zandecki, M., Laı̈, J.-L., Leleu, X., Jouet, J.-P., Bauters, F., et al. (2001) · Blood · doi:10.1182/blood.v97.6.1566 · Cited by 312
Lenhoff, S., Hjorth, M., Holmberg, E. C., Turesson, I., Westin, J., Nielsen, J. L., Wislöff, F., Brinch, L., Carlson, K. E., Carlsson, M. S., et al. (2000) · PubMed · doi:10.1182/blood.v95.1.7 · Cited by 310
Research works printed but not linked: 7
- Morgan G, Selby P. Myeloma. In: Souhami R, Tannock I, Hohenberger P, Horiot J-C, eds. Oxford textbook of oncology. 2nd ed. Vol. 2. Oxford, England: Oxford University Press, 2001:2419-55.
- Lenhoff S, 2000, Blood, 95, 7
- Fermand J-P, 1999, Blood, 94, 396a
- Review manager (RevMan), version 4.1. Oxford, England: Cochrane Collaboration, 2000.
- Blade J, 2001, Blood, 98, 815a
- Segeren CM, 2001, Blood, 98, 815a
- Fermand J-P, 2001, Blood, 98, 815a
Cited by
Items 801–900 of 1,000
A multicenter phase II study of single-agent enzastaurin in previously treated multiple myeloma
Jourdan, É., Leblond, V., Maisonneuve, H., Benhadji, K. A., Hossain, A. M., Nguyen, T. S., Wooldridge, J. E., & Moreau, P. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.861066 · Cited by 18
Management of mobilization failure in 2017
Namdaroğlu, S., Korkmaz, S., & Altuntaş, F. (2017) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2017.11.017 · Cited by 18
“[2] Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al.”
BackgroundGalán‐Olleros, M., Marco, J., Oteo, D., Cristóbal-Bilbao, R., Manrique, E., García‐Maroto, R., Marco, F., & Cebrián-Parra, J. L. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08819-6 · Cited by 18
Rohatgi, N., Du, X. L., Coker, A. L., Moyé, L. A., Wang, M. L., & Fang, S. (2007) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3180592a30 · Cited by 18
Ayuk, F., Pérez‐Simón, J. A., Shimoni, A., Sureda, A. M., Zabelina, T., Schwerdtfeger, R., Martino, R., Sayer, H. G., Alegre, A. M., Lahuerta, J. J., et al. (2008) · Haematologica · doi:10.3324/haematol.12665 · Cited by 18
“001 Median follow-up (range) 32 months (3-80) 27 months (3-65) 0.”
Nieto, Y. L. (2003) · Cancer chemotherapy and biological response modifiers · doi:10.1016/s0921-4410(03)21008-5 · Cited by 18
Stem cell transplantation for multiple myeloma: current and future status
Giralt, S. (2012) · Hematology · doi:10.1179/102453312x13336169156258 · Cited by 17
The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring “Multiple Myelomas”
Solimando, A. G., Vià, M. D., Bolli, N., & Steinbrunn, T. (2022) · Cancers · doi:10.3390/cancers14133271 · Cited by 17
“MM remains an incurable disease, despite conventional therapies [9,10] and considerable improvements in novel therapeutic approaches [11].”
BackgroundAdvances in the Autologous and Allogeneic Transplantation Strategies for Multiple Myeloma
Nishihori, T., & Alsina, M. (2011) · Cancer Control · doi:10.1177/107327481101800406 · Cited by 20
Review of thalidomide in the treatment of newly diagnosed multiple myeloma.
Cavallo, F., Boccadoro, M., & Palumbo, A. P. (2007) · PubMed Central · Cited by 19
Corso, A., Barbarano, L., Mangiacavalli, S., Spriano, M., Alessandrino, E. P., Cafro, A. M., Pascutto, C., Varettoni, M., BERNASCONI, P. P., Grillo, G., et al. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190903452826 · Cited by 17
Autologous stem cell transplantation in patients with high‐risk plasmacytoma
Jantunen, E., Koivunen, E., Putkonen, M., Siitonen, T., Juvonen, E., & Nousiainen, T. (2005) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2004.00404.x · Cited by 17
“Although the remission status of these patients is sometimes difficult to judge, this figure seems to be higher than the remission frequency with single or tandem ASCT in patients with MM (1, 2, 15, 16).”
BackgroundHigh Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis
Sanchorawala, V. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.08.013 · Cited by 17
Allogeneic transplantation in multiple myeloma
Gahrton, G., & Krishnan, A. Y. (2013) · Expert Review of Hematology · doi:10.1586/17474086.2014.857270 · Cited by 17
Maintenance Therapy for Multiple Myeloma
McCarthy, P. L., & Palumbo, A. P. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.06.006 · Cited by 19
Schmid, A., Friess, D., Taleghani, B. M., Keller, P., Mueller, B. U., Baerlocher, G. M., Leibundgut, K., & Pabst, T. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.927454 · Cited by 17
Biran, N., Rowley, S. D., Vesole, D. H., Zhang, S., Donato, M. L., Richter, J. R., Skarbnik, A. P. Z., Pecora, A. L., & Siegel, D. S. D. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.08.017 · Cited by 17
“3%) had t(4;14)), 22 (69%) had no adverse features, and 6 (18.”
BackgroundRole of stem cell transplant and maintenance therapy in plasma cell disorders
McCarthy, P. L., & Holstein, S. A. (2016) · Hematology · doi:10.1182/asheducation-2016.1.504 · Cited by 18
Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?
Wallis, W. D., & Qazilbash, M. H. (2017) · World Journal of Transplantation · doi:10.5500/wjt.v7.i5.250 · Cited by 18
Ding, X., Huang, W., Peng, Y., Fan, H., Zhu, Y., Liu, X., Yang, Y., Guo, Q., Qiu, L., Dai, Y., et al. (2020) · Annals of Hematology · doi:10.1007/s00277-019-03800-0 · Cited by 17
Aladağ, E., Demiroğlu, H., Büyükaşık, Y., Turgut, M., Aksu, S., Sayınalp, N., Haznedaroğlu, İ. C., Ozcebe, O. I., & Göker, H. (2020) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2001-173 · Cited by 17
Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma
Elnair, R. A., & Holstein, S. A. (2021) · Drugs · doi:10.1007/s40265-021-01514-0 · Cited by 18
“Historically, the use of high-dose melphalan and stem cell support has been associated with improved progression-free survival (PFS) and overall survival (OS) when compared to conventional chemotherapy [11, 12] and MM remains the most common indication for autologous stem cell transplant (ASCT).”
BackgroundJónsdóttir, G., Björkholm, M., Turesson, I., Hultcrantz, M. L., Diamond, B. T., Porwit‐MacDonald, A., Landgren, O., & Kristinsson, S. Y. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13650 · Cited by 18
Bergin, K., Wellard, C. J., Augustson, B. M., Cooke, R. E., Blacklock, H. A., Harrison, S. J., Ho, P. J., King, T., Quach, H., Mollee, P. N., et al. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01308-8 · Cited by 17
Polo, V. A., Mantilla, W. A., Idrobo, H., Sossa, C., Salazar, L. A., Peña, Á., Herrera, J. M., Guerrero, P., Espinosa, D. L., Quintero, G., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.12.009 · Cited by 17
Royle, K., Coulson, A. B., Ramasamy, K., Cairns, D. A., Hockaday, A., Quezada, S. A., Drayson, M. T., Kaiser, M., Owen, R. G., Auner, H. W., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-063037 · Cited by 19
Self-citationParty, T. K. M. M. W., Lee, S. S., Suh, C., Kim, B.-S., Chung, J.-S., Joo, Y., Ryoo, H.-M., Do, Y. R., Jin, J., Kang, H. J., et al. (2010) · Annals of Hematology · doi:10.1007/s00277-010-0943-z · Cited by 17
Recent advances in the management of multiple myeloma
Munshi, N. C. (2004) · Seminars in Hematology · doi:10.1053/j.seminhematol.2004.03.002 · Cited by 19
Nishihori, T., Ochoa-Bayona, J. L., Kim, J., Pidala, J., Shain, K. H., Baz, R., Sullivan, D. M., Jim, H., Anasetti, C., & Alsina, M. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.37 · Cited by 17
Serum M‐spike and transplant outcome in patients with multiple myeloma
Dingli, D., Pacheco, J. M., Dispenzieri, A. A., Hayman, S. R., Kumar, S. K., Lacy, M. Q., Gastineau, D. A., & Gertz, M. A. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00499.x · Cited by 17
“− = ( 3 ) For patients who achieved CR, given the log-linear relationship observed in responding”
BackgroundFrequency of altered monoclonal protein production at relapse of multiple myeloma
Hobbs, J. A. R., Drayson, M. T., Sharp, K., Harding, S. J., Bradwell, A. R., & Mead, G. P. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07952.x · Cited by 17
“We have studied changes in M-Ig and sFLCs at relapse and compared the frequency of LCE in patients treated on intensive (I) versus non-intensive (NI) chemotherapy regimens in the UK MRC Myeloma VII trial (Child et al, 2003).”
BackgroundSelf-citationEvolving therapeutic paradigms for multiple myeloma: back to the future
Cherry, B. M., Korde, N., Kwok, M., Roschewski, M. J., & Landgren, O. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.717277 · Cited by 18
Valtola, J., Silvennoinen, R. H., Ropponen, A., Siitonen, T., Säily, M., Sankelo, M., Terävä, V., Putkonen, M., Kuittinen, T., Pelkonen, J., et al. (2016) · Transfusion · doi:10.1111/trf.13574 · Cited by 17
D’Souza, A., Zhang, M.-J., Huang, J., Fei, M., Pasquini, M. C., Hamadani, M., & Hari, P. (2017) · Leukemia · doi:10.1038/leu.2017.185 · Cited by 17
“This is in keeping with practice changing clinical trials supporting the use of AHCT in the upfront setting during this period.(5, 6) Figure 1A shows the various induction regimen trends over the period.”
ResultGössi, U., Jeker, B., Taleghani, B. M., Bacher, U., Novak, U., Betticher, D. C., Egger, T., Zander, T., & Pabst, T. (2018) · Hematological Oncology · doi:10.1002/hon.2490 · Cited by 17
“The analysis indicated that ASCT2 (P = .031), lenalidomide maintenance (P = .018), and the achievement of at least VGPR2 after salvage treatment before ASCT2 (P = .027) were independent risk factors for better OS.”
BackgroundMethodInfluentialUpdated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide
Schoenbeck, K. L., & Wildes, T. M. (2020) · Clinical Interventions in Aging · doi:10.2147/cia.s196087 · Cited by 18
“ASCT is a mainstay of multiple myeloma treatment in those younger than 65 years old, as randomized trials show improved overall survival (OS) and progression-free survival (PFS) compared to standard therapy.(7,8) Since patients older than 65 years were not included in the pivotal trials establishing ASCT in myeloma, t…”
ResultAutologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?
Minnie, S. A., & Hill, G. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.651288 · Cited by 21
Musto, P., Falcone, A. P., Sanpaolo, G., Guglielmelli, T., Zambello, R., Balleari, E., Catalano, L., Spriano, M., Cavallo, F., Sala, A. L., et al. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.06.027 · Cited by 17
Stella-Holowiecka, B., Czerw, T., Holowiecka-Goral, A., Giebel, S., Wojnar, J., & Hołowiecki, J. (2007) · Transplantation Proceedings · doi:10.1016/j.transproceed.2007.08.052 · Cited by 17
153Sm: its use in multiple myeloma and report of a clinical experience
Abruzzese, E., Iuliano, F., Trawinska, M. M., & Maïo, M. D. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.9.1379 · Cited by 17
“High-dose chemotherapy with stem-cell support, although not curative, improves complete remission rates and prolongs median overall survival by ∼ 12 months [9,10] , and it is still considered the conventional therapy in younger patients [11] .”
BackgroundNeri, P. E., Yasui, H., Hideshima, T., Tassone, P., Raje, N. S., Catley, L. P., Ishitsuka, K., Blotta, S., Kiziltepe, T., Ocio, E. M., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06122.x · Cited by 18
“…alkylating agents, anthracyclines (Gregory et al, 1992) and high-dose chemotherapy combined with stem cell transplantation (Attal et al, 2003; Child et al, 2003; Kyle & Rajkumar, 2004), multiple myeloma (MM) remains incurable due to intrinsic and acquired drug resistance (Grogan et al, 1993;…”
BackgroundStrategies to improve the outcome of stem cell transplantation in multiple myeloma
Catley, L. P., & Anderson, K. C. (2004) · The Hematology Journal · doi:10.1038/sj.thj.6200322 · Cited by 18
Thalidomide in multiple myeloma
García‐Sánz, R. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.2.195 · Cited by 21
“Since the discovery that high-dose therapy was feasible in multiple-myeloma patients [5], several reports have demonstrated clinical advantages of the strategy [6,7], although not all studies have demonstrated a clear advantage in terms of survival [8,9], and current improvements could be partly attributed to supporti…”
BackgroundA Novel HSV-1 Virus, JS1/34.5−/47−, Purges Contaminating Breast Cancer Cells From Bone Marrow
Hu, J. C. C., Booth, M. J., Tripuraneni, G., Davies, D. C., Zaidi, S. A. A., Bella, M. T. D., Slade, M. J., Marley, S. B., Gordon, M. Y., Coffin, R. S., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1228 · Cited by 17
Lenalidomide and its role in the management of multiple myeloma
Falco, P., Cavallo, F., Larocca, A., Liberati, A. M., Musto, P., Boccadoro, M., & Palumbo, A. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.6.865 · Cited by 17
Current Standards for First-Line Therapy of Multiple Myeloma
Jagannath, S. (2007) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2007.s.024 · Cited by 18
Treatment advances in multiple myeloma
Tricot, G. J. K., Barlogie, B., & van Rhee, F. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04851.x · Cited by 17
“The superiority of high dose over standard dose chemotherapy has been demonstrated in two randomized trials (Attal et al, 1996; Child et al, 2003): a comparison with matched historical controls (Barlogie et al, 1997) and a population-based study (Lenhoff et al, 2000).”
Lamm, W. W., Drach-Schauer, B., Eder, S., & Drach, J. W. (2013) · Oncology · doi:10.1159/000355197 · Cited by 17
Burnette, B. L., Dispenzieri, A. A., Kumar, S. K., Harris, A. M., Sloan, J. A., Tilburt, J. C., Kyle, R. A., & Rajkumar, S. V. (2013) · Cancer · doi:10.1002/cncr.28340 · Cited by 18
“all survival benefit of at least 1 year compared with conventional therapy.(23,24) Although earlier experiences with maintenance after both conventional chemotherapy and high-dose therapy had previously been disappointing, the development of the immunomodulating agents thalidomide and lenalidomide as well as the prote…”
BackgroundWannesson, L., Luthi, F., Zucca, E., Rosselet, A., Baglioni, M., Marelli, L., Ghielmini, M. E. G., & Ketterer, N. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.545462 · Cited by 16
The Role of High-Dose Therapy With Autologous Stem Cell Support in the Era of Novel Agents
Attal, M., & Harousseau, J. (2009) · Seminars in Hematology · doi:10.1053/j.seminhematol.2009.02.006 · Cited by 18
Sheppard, D., Tay, J., Palmer, D. S., Xenocostas, A., Doulaverakis, C., Huebsch, L. B., McDiarmid, S. A., Tinmouth, A. T., Mallick, R., Martin, L., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.11.016 · Cited by 16
Hematopoietic Stem Cell Transplantation in Multiple Myeloma
Harousseau, J. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0063 · Cited by 17
“To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation at http://www.”
BackgroundVarma, A., Biritxinaga, L., Saliba, R. M., Stich, M., Jauch, S. F., Afrough, A., Honhar, M., Popat, U., Shafi, M. A., Shah, N. D., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.01.005 · Cited by 16
Sauer, S., Erdmann, K., Jensen, A. D., Wennmann, M., Pavel, P., Jordan, K., Schmitt, A., Kriegsmann, M., Wuchter, P., Goldschmidt, H., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.06.025 · Cited by 16
Multiple myeloma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Harousseau, J., & Dreyling, M. H. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn088 · Cited by 18
Fonseca, R., & Rajkumar, S. V. (2008) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2008.n.046 · Cited by 16
Vogl, D. T., Liu, S. V., Chong, E. A., Luger, S. M., Porter, D. L., Schuster, S. J., Tsai, D. E., Perl, A. E., Loren, A. W., Goldstein, S. C., et al. (2007) · American Journal of Hematology · doi:10.1002/ajh.21038 · Cited by 16
“Introduction High-dose melphalan with autologous stem cell support confers an overall survival advantage in the treatment of myeloma compared to prolonged courses of standard dose chemotherapy [1,2].”
BackgroundKim, H. J., Yoon, S., Lee, D. S., Sohn, S. K., Eom, H., Lee, J. L., Chung, J. S., Kım, K., Suh, C., Won, J.-H., et al. (2011) · Annals of Hematology · doi:10.1007/s00277-011-1298-9 · Cited by 18
Meehan, K. R., Talebian, L., Tosteson, T. D., Hill, J. M., Szczepiorkowski, Z. M., Sentman, C. L., & Ernstoff, M. S. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.08.018 · Cited by 16
“INTRODUCTION We developed ex vivo expansion methods to enrich for Multiple myeloma is incurable with standard therapy [1,2].”
MethodGüner, Ș. I., Yanmaz, M. T., Selvi, A., & Afşar, Ç. U. (2016) · Hematology Reports · doi:10.4081/hr.2016.6319 · Cited by 16
Ri, M., Matsue, K., Sunami, K., Shimazaki, C., Hayashi, A., Sunaga, Y., Sasaki, T., & Suzuki, K. (2017) · International Journal of Hematology · doi:10.1007/s12185-017-2255-8 · Cited by 16
Şahin, U., & Demirer, T. (2017) · Journal of Clinical Apheresis · doi:10.1002/jca.21591 · Cited by 18
“[2] Child JA, Morgan GJ, Davies FE, Medical Research Council”
BackgroundPeña, C., Rojas, C., Rojas, H., Soto, P., Cardemil, D., Aranda, S., Contreras, C., Rocca, G. L., Russo, M., Pérez, C., et al. (2018) · Revista médica de Chile · doi:10.4067/s0034-98872018000700869 · Cited by 16
Nikolaenko, L., Chhabra, S., Biran, N., Chowdhury, A., Hari, P., Krishnan, A. Y., & Richter, J. R. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.01.010 · Cited by 17
García‐Sánz, R., Mateos, M., & Miguel, J. F. S. (2007) · Medicina Clínica · doi:10.1157/13107365 · Cited by 36
Amin, A. M., Soliman, S. E., & El‐Aziz, H. A. (2009) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.1698 · Cited by 16
Rodriguez, A. L., Tariman, J. D., Enecio, T., & Estrella, S. M. (2007) · Clinical journal of oncology nursing · doi:10.1188/07.cjon.579-589 · Cited by 16
Hematopoietic Stem Cell Transplantation
Bishop, M. R., & Pavletic, S. Z. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50036-1 · Cited by 16
Treatment of multiple myeloma: An emphasis on new developments
Kyle, R. A., & Rajkumar, S. V. (2006) · Annals of Medicine · doi:10.1080/07853890500472078 · Cited by 16
“Autologous stem cell transplantation increases the likelihood of a complete response and prolongs disease-free survival and overall survival compared with chemotherapy (7,8).”
BackgroundEvolving treatment strategies for myeloma
Morgan, G. J., & Davies, F. E. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602341 · Cited by 20
Self-citationBesliu, C., Tănase, A., Rotaru, I., Espinoza, J., Vidal, L., Poelman, M., Juan, M., de Larrea, C. F., & Saini, K. S. (2025) · Cancers · doi:10.3390/cancers17030525 · Cited by 17
“With the introduction of ASCT with high-dose chemotherapy (HDCT), the median survival improved to 7 years [42].”
Baumann, P., Müller, K., Mandl–Weber, S., Leban, J. J., Doblhofer, R., Ammendola, A., Baumgartner, R., Oduncu, F. S., & Schmidmaier, R. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07570.x · Cited by 15
Kim, S. S., Renteria, A. S., Steinberg, A. S., Banoff, K. M., & Isola, L. M. (2014) · Cytotherapy · doi:10.1016/j.jcyt.2014.05.003 · Cited by 16
“Autologous stem cell transplantation (ASCT) is an effective treatment for multiple myeloma (MM) [1,2].”
BackgroundPalumbo, A. P., Offidani, M., Patriarca, F. F., Petrucci, M. T., & Cavo, M. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.915545 · Cited by 15
Pavlů, J., Auner, H. W., Szydlo, R., Sevillano, B., Palani, R., O’Boyle, F., Chaidos, A., Jakob, C., Kanfer, E., Macdonald, D., et al. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.113 · Cited by 15
Dispenzieri, A. A., D’Souza, A., Gertz, M. A., Laumann, K. M., Wiseman, G. A., Lacy, M. Q., LaPlant, B. R., Buadi, F. K., Hayman, S. R., Kumar, S. K., et al. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.164 · Cited by 15
Therapy-related myeloid neoplasms after treatment for plasma-cell disorders
Chung, A., & Liedtke, M. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.02.003 · Cited by 15
Ganesan, S., Palani, H. K., Balasundaram, N., David, S., Devasia, A. J., George, B., & Mathews, V. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0431 · Cited by 17
“In the younger patients, over the past 2 decades, high-dose chemotherapy along with autologous stem cell transplantation has been the standard of care (1, 2).”
BackgroundLee, H., Hyun, S. H., Cho, Y. S., Moon, S. H., Choi, J. Y., Kım, K., & Lee, K.-H. (2023) · Scientific Reports · doi:10.1038/s41598-023-34653-3 · Cited by 16
Guo, W., Zhan, A., Mery, D. E., Munshi, M. N., Makhoul, O., Baily, C., Zangari, M., Tricot, G. J. K., Peng, H., & Shaughnessy, J. D. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011096 · Cited by 15
Abidi, M. H., Agarwal, R., Ayash, L. J., Deol, A., Al-Kadhimi, Z. S., Abrams, J., Cronin, S. M., Ventimiglia, M., Lum, L. G., Zonder, J. A., et al. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.03.010 · Cited by 15
Benevolo, G., Larocca, A., Gentile, M., Pregno, P., Gay, F., Botto, B., Frairia, C., Evangelista, A., Morabito, F., Boccadoro, M., et al. (2010) · Cancer · doi:10.1002/cncr.25743 · Cited by 15
Girnius, S. K., Seldin, D. C., Skinner, M. M., Finn, K. T., Quillen, K., Doros, G. D., & Sanchorawala, V. (2009) · Annals of Hematology · doi:10.1007/s00277-009-0874-8 · Cited by 15
All transplantation-eligible patients with myeloma should receive ASCT in first response
Moreau, P., & Attal, M. (2014) · Hematology · doi:10.1182/asheducation-2014.1.250 · Cited by 16
Farag, S. A., Jeker, B., Bacher, U., Taleghani, B. M., Mueller, B. U., Novak, U., & Pabst, T. (2018) · Hematological Oncology · doi:10.1002/hon.2546 · Cited by 15
“Autologous stem cell transplantation may be single or tandem, while it remains a matter of continued debate how best to routinely incorporate a tandem transplant in the treatment algorithm of myeloma patients.(22,29,30) Whereas the IMWG criteria suggest an ASCT2 in those patients who fail to achieve a VGPR after ASCT,…”
BackgroundSu, B., Zhu, X., Jiang, Y., Wang, L., Zhao, N., Ran, X., Zheng, X., & Guo, H. M. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1543874 · Cited by 16
“after primary therapy for eligible patients [1,2].”
Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years
Bashir, Q., Chamoun, K., Milton, D. R., Khan, M., Ahmed, S., Mehta, R. S., Popat, U., Kebriaei, P., Nieto, Y. L., Oran, B., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1633633 · Cited by 15
Terpos, E., Ntanasis‐Stathopoulos, I., Ρούσσου, Μ., Kanellias, N., Fotiou, D., Migkou, M., Eleutherakis‐Papaiakovou, E., Gavriatopoulou, M., Kastritis, E., & Dimopoulos, M. A. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04060-z · Cited by 15
Huang, C.-Y., Wu, M., Kuo, Y., Tou, S.-I., & Yen, H. (2020) · Integrative Cancer Therapies · doi:10.1177/1534735420943280 · Cited by 15
Pawarode, A., Mineishi, S., Reddy, P. R., Braun, T., Khaled, Y. A., Choi, S. W., Magenau, J. M., Harris, A. C., Connelly, J. A., Kitko, C. L., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.07.021 · Cited by 16
“First-line consolidative high-dose therapy and autologous (Auto) hematopoietic cell transplantation (HCT) have been shown to prolong myeloma progression [2-4] and are currently considered a standard of care [5,6].”
BackgroundZeiser, R., & Finke, J. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.11.038 · Cited by 15
Molecular Monitoring of Minimal Residual Disease in Patients with Multiple Myeloma
Fenk, R. R., Haas, R. R., & Kronenwett, R. (2004) · Hematology · doi:10.1080/10245330310001638965 · Cited by 15
“High-dose chemotherapy (HDT) with autologous blood stem cell transplantation (SCT) lead to improved response rates and survival in patients with MM in comparison to conventional chemotherapy [1,2].”
BackgroundBiology and Treatment of Multiple Myeloma
Tosi, P., Gamberi, B., & Giuliani, N. (2006) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2005.09.008 · Cited by 15
D’Sa, S., Yong, K., Kyriakou, C., Bhattacharya, S., Peggs, K. S., Foulkes, B., Watts, M., Ings, S. J., Ardeshna, K. M., Goldstone, A. H., et al. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04981.x · Cited by 15
“Autologous stem cell transplantation (ASCT) can improve outcome in patients up to the age of 65 years of age when compared with conventional chemotherapy (Attal et al, 1996; Child et al, 2003).”
BackgroundWu, J. Y., Ernstoff, M. S., Hill, J. M., Cole, B. F., & Meehan, K. R. (2006) · Cytotherapy · doi:10.1080/14653240600620218 · Cited by 15
Bortezomib for multiple myeloma
Popat, R., Joel, S., Oakervee, H. E., & Cavenagh, J. D. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.10.1337 · Cited by 15
“Using conventional therapies, MM is incurable, with a median overall survival of 3 – 4 years, but this may be extended by 18 months in the minority that are able to tolerate high-dose therapy (HDT) supported by peripheral blood stem-cell rescue (PBSCR) [2].”
BackgroundMultiple Myeloma, 2004 — One or Two Transplants?
Stadtmauer, E. A. (2003) · New England Journal of Medicine · doi:10.1056/nejme038187 · Cited by 15
Stem cell transplantation for multiple myeloma: current and future status
Giralt, S., & Bensinger, W. (2013) · Leukemia Supplements · doi:10.1038/leusup.2013.3 · Cited by 14
Martino, M. V., Postorino, M., Gallo, G. A., Messina, G., Neri, S., Piro, E., Gentile, M., Moscato, T., Monteleone, R., Fedele, R., et al. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.11.009 · Cited by 14
Metadata
- Authors
- Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J.
- Affiliations
- University of Leeds (GB)
- University of Birmingham (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-05-08
- Volume
- 348
- Issue
- 19
- Pages
- 1875-1883
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2102591890
- Semantic Scholar
- 5d90e1ff237e9db8f41e6e1e264450eed3f77e40
- Cited by
- 1,768
- References
- 23
- Citations by year
- 2026: 17 · 2025: 26 · 2024: 34 · 2023: 36 · 2022: 41 · 2021: 57 · 2020: 83 · 2019: 46 · 2018: 71 · 2017: 76 · 2016: 73 · 2015: 71 · 2014: 81 · 2013: 103 · 2012: 94
- FWCI
- 53.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- multiple myeloma, high-dose chemotherapy, autologous stem cell transplantation, first-line therapy, complete response, overall survival, progression-free survival, beta2-microglobulin, prognostic factors, previously untreated myeloma
- MeSH terms
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carmustine, Cause of Death, Combined Modality Therapy, Cyclophosphamide, Doxorubicin, Female, Humans, Male, Melphalan, Middle Aged, Multiple Myeloma, Prognosis, Survival Analysis, Hematopoietic Stem Cell Transplantation, Antineoplastic Agents, Alkylating
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.